PT  - JOURNAL ARTICLE
AU  - Saleska, Jessica Londeree
AU  - Bryant, Corey
AU  - Kolobaric, Antonija
AU  - Colwell, Christopher S.
AU  - Loewy, Derek
AU  - Chen, Jeff
AU  - Pauli, Emily K.
TI  - The safety and relative effectiveness of non-psychoactive cannabinoid formulations for the improvement of sleep: a double-blinded, randomized controlled trial
AID  - 10.1101/2023.01.20.23284842
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.01.20.23284842
4099  - http://medrxiv.org/content/early/2023/01/23/2023.01.20.23284842.short
4100  - http://medrxiv.org/content/early/2023/01/23/2023.01.20.23284842.full
AB  - The objective of this randomized, double-blinded controlled trial was to evaluate the safety and relative effects of different formulations containing Cannabidiol (CBD) and melatonin, with and without the addition of minor cannabinoids, on sleep. Participants (N=1,793 adults experiencing symptoms of sleep disturbance) were assigned to receive a 4-week supply of 1 of 6 products (all capsules) containing either 15mg CBD or 5mg melatonin, alone or in combination with minor cannabinoids. Sleep disturbance was assessed using Patient-Reported Outcomes Measurement Information System (PROMIS™) Sleep Disturbance SF 8A, administered via weekly online surveys. All formulations exhibited a favorable safety profile (12% of participants reported a side effect and none were severe) and led to significant improvements in sleep disturbance (p<0.001 in within-group comparisons). Most participants (56% to 75%) across all formulations experienced a clinically important improvement in their sleep quality. There were no significant differences in effect, however, between 15mg CBD isolate and formulations containing 15mg CBD and 15mg Cannabinol (CBN), alone or in combination with 5 mg Cannabichromene (CBC). There were also no significant differences in effect between 15mg CBD isolate and formulations containing 5 mg melatonin, alone or in combination with 15mg CBD and 15mg CBN. Our findings suggest that chronic use of a low dose of CBD is safe and could improve sleep quality, though these effects do not exceed that of 5 mg melatonin. Moreover, the addition of low doses of CBN and CBC may not improve the effect of formulations containing CBD or melatonin isolate.Competing Interest StatementThe authors have no conflicts of interest to declare. This research was supported by Open Book Extracts (OBX). OBX provided direction into the study design through development of the study arms and the primary objective of the study. They had no role in the conduct of the study; collection, management, analysis, and interpretation of the data; or the preparation, review or approval of the manuscript. Clinical TrialNCT05552898Funding StatementThis research was supported by Open Book Extracts (OBX). OBX provided direction into the study design through development of the study arms and the primary objective of the study. They had no role, however, in the conduct of the study; collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of Sterling Review Board gave ethical approval of this work [Identification number: 9760-EKPauli].I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors